October 22, 2018 Clinical Research/Diagn. M&A, Partnerships

Announcement of Participation in AMED Project “Research and development of core technologies for gene and cell therapy”

2018/10/22 Kusatsu/Shiga, Japan — October 22, 2018 – Takara Bio Inc. announces that it is participating in “Research and development of core technologies for gene and cell therapy” (Project) undertaken by Japan Agency for Medical Research and Development (AMED: https://www.amed.go.jp/en/index.html) since FY2018, under which Takara Bio will work on the development for large-scale production technologies of... Read more

August 22, 2018 Licensing, IP, and Legal M&A, Partnerships

Takara Bio entered into a licensing agreement relating to Oncolytic Virus "Canerpaturev" with Dong-A ST, South Korea

This article is translated from press release in Japanese for your convenience. Forward-Looking Statements Statements in this news release, other than those based on historical fact, concerning the current plans, prospects, strategies and expectations of the Company and its Group represent forecasts of future results. While such statements are based on the conclusions of management... Read more

July 25, 2018 Clinical Research/Diagn. Licensing, IP, and Legal

Takara Bio granted manufacturing license from the Swedish Medical Product Agency for clinical-grade human embryonic stem cell line derivation and banking

MOUNTAIN VIEW, Calif., July 25, 2018 /PRNewswire/ — Takara Bio announced today that the Medical Products Agency (“MPA”), the Swedish national authority responsible for regulation and surveillance of the development, manufacturing and marketing of drug and other medical products, granted a manufacturing license for derivation and banking of human embryonic stem (hES) cells to be produced under GMP... Read more

July 18, 2018 Cell Analysis Tools Licensing, IP, and Legal Life Science Tools

Takara Bio strengthens its IP position on single cell RNA-seq

MOUNTAIN VIEW, Calif., July 18, 2018 /PRNewswire/ — Takara Bio USA, Inc., (TBUSA, formerly Clontech Laboratories, Inc.), a wholly owned subsidiary of Takara Bio Inc., is proud to announce that patent JP6336080B—covering the Smart-seq2 method, developed by Rickard Sandberg and exclusively licensed to TBUSA by the Ludwig Institute—has been awarded by the Japan Patent Office. Additional patents regarding the Smart-seq2 technology... Read more

June 8, 2018 Uncategorized

【Delayed】Announcement on revision of Takara Bio Medium-Term Management Plan FY2020

This article is translated from press release in Japanese for your convenience. Forward-Looking Statements Statements in this news release, other than those based on historical fact, concerning the current plans, prospects, strategies and expectations of the Company and its Group represent forecasts of future results. While such statements are based on the conclusions of management... Read more

February 19, 2018 Atomic Spectroscopy Product Launch

Takara Bio to Establish a New Facility for the Research and Manufacturing of Regenerative Medical Products

Takara Bio to Establish a New Facility for the Research andManufacturing of Regenerative Medical Products January 30, 2018 – Takara Bio’s Board of Directors resolved today to establish a new facility for the research and manufacturing of regenerative medical products in coordination with the expansion of existing research and manufacturing facilities at the company’s head... Read more

January 30, 2018 Clinical Research/Diagn.

Takara Bio to Establish a New Facility for the Research and Manufacturing of Regenerative Medical Products

2018/02/19 January 30, 2018 – Takara Bio’s Board of Directors resolved today to establish a new facility for the research and manufacturing of regenerative medical products in coordination with the expansion of existing research and manufacturing facilities at the company’s head office site in Kusatsu, Shiga. Total project cost is expected to be around 7.3... Read more

January 30, 2018 Microscopy PR/Corporate

Consolidated Financial Statements for the Third Quarter Ended December 31, 2017

3Q Results, December 31, 2017（PDF） This article is translated from press release in Japanese for your convenience. Forward-Looking StatementsStatements in this news release, other than those based on historical fact, concerning the current plans, prospects, strategies and expectations of the Company and its Group represent forecasts of future results. While such statements are based on... Read more

January 30, 2018 Microscopy PR/Corporate

Summary of Consolidated Financial Statements for the Third Quarter Ended December 31, 2017

3Q Results, December 31, 2017（PDF） This article is translated from press release in Japanese for your convenience. Forward-Looking StatementsStatements in this news release, other than those based on historical fact, concerning the current plans, prospects, strategies and expectations of the Company and its Group represent forecasts of future results. While such statements are based on... Read more